Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostics and clinical laboratory services. self-described as advancing laboratory services.

Avalon GloboCare Corp.

Domain Not Resolving

DNSSEC

Laravel

Luisa Ingargiola

Chief Financial Officer

David K Jin

President/CEO/Co-Founder

Health Care Companies With Fewer Than 50 Employees (Top 10K)

Health Care Public Companies With Less Than $10M in Revenue

New Jersey Companies With Less Than $1B in Revenue (Top 10K)

Greater New York Area Companies With Fewer Than 1000 Employees (Top 10K)

Avalon GloboCare Corp is a clinical-stage biotech developer and healthcare service provider dedicated to promote and empower high impact, transformative biotechnology and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab."

Post-IPO Equity - Avalon GloboCare Corp

Freehold

New Jersey

United States

North America

Avalon GloboCare Corp

Avalon Globocare Corp trading halted, news pending

Avalon GloboCare announces 1-for-15 reverse stock split as part of Nasdaq compliance plan

Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction

Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us

Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference

Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 ...

Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report

Avalon GloboCare receives Nasdaq notice of non-compliance

Avalon GloboCare Acquires Leading Beijing Exosome Technology Company

News Brief: Avalon GloboCare Corp.

Avalon GloboCare offers a range of clinical testing services including bloodwork, anatomic pathology, urine toxicology, and pharmacogenomics testing.

A handheld device for detecting acetone levels in breath, indicating ketosis status, registered as a Class I medical device with the FDA.

Joint intellectual property with MIT for designing water-soluble variant cytokine receptors showing binding affinity to respective cytokines.

Provides diagnostic tests including drug testing, toxicology, and wellness testing with capabilities like STAT blood testing and genetic testing.

Offers PCR testing for COVID-19 using advanced instrumentation for accurate and fast results.

Uses real-time PCR to identify genetic variants affecting medication metabolism, aiding in personalized medication management.

India

Asia

Sweden

Europe

Pakistan

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 15, 2024 3:10 PM	66aa6143
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 15, 2024 3:10 PM	11ce2aa1
crunchbase trigger	general	Nov 27, 2024 12:50 PM	3e4704ef
crunchbase profile	general	Nov 28, 2024 8:58 AM	483c634d
li profile	general
translate crunchbase fundingrounds	general	Nov 28, 2024 10:18 AM	83b71059
peers	general	Oct 15, 2024 3:10 PM	cc730f2d
news basic	general	Oct 15, 2024 3:10 PM	7e489a27
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AVALON-GLOBOCARE

Avalon GloboCare Corp.

Last Close

0.63

10/11 05:00

Market Cap

5.26M

Beta: -

Volume Today

432.17K

Avg: -